Blog
RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot
In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review ...
Blog
Patient voice in RWE: Generating evidence that will impact payer and HTA decision-making
With the rise of patient-centered medicine and accelerated approvals, health technology ...
Blog
RWE Guidance Watch: IMPACT HTA publishes recommendations on the use of RWE in HTA
As researchers await comprehensive guidance on the use of real-world evidence (RWE)—and ...
Blog
An update on efforts to standardize and democratize RWE: Q&A with Dr. Nirosha Mahendraratnam Lederer
As real-world evidence (RWE) adoption continues to ramp up across health care, ...
Blog
Research spotlight: Gilead Sciences and Aetion use RWE to assess the comparative effectiveness of remdesivir for COVID-19
As COVID-19 continues to evolve, frontline health care workers are eager for real-world ...
Blog
Using RWE to characterize diseases as novel treatments become available: Q&A with Dr. Maria Schneeweiss
As novel therapies come to market, especially in disease areas that aren’t as well ...
Blog
Research spotlight: Using RWD sources to describe the patient burden of a poorly understood rare disease
This month, Aetion and Boehringer Ingelheim published two co-authored papers which ...
Blog
Research spotlight: Organized structure of RWE best practices
In the last five to 10 years, stakeholders from around the globe have launched ...
Blog
How NICE is approaching guidelines for RWE generation: Q&A with Dr. Páll Jónsson
In its recently announced five-year strategy, the UK’s National Institute for Health and ...
Blog
Introducing the RWE Alliance: How a cross-industry coalition aims to advance RWE policy
The last several years have been foundational in the effort to advance the use of ...
Blog
How leading-edge teams are using RWE to accelerate drug development: A conversation with Janssen R&D and Sanofi
The majority of biopharma organizations are investing in real-world evidence (RWE) ...
Blog
How payers and providers can leverage RWE: Q&A with Bill Guptail, SVP of Value-Based Care, Aetion
As payers and providers continue to navigate value-based agreements and strive to improve ...
Blog
How using an RWE platform can support building regulatory-grade ECAs
An external control arm (ECA) study is a cutting-edge pharmacoepidemiologic design that ...
Blog
RWE plays an integral role in NICE’s five-year strategy
For the UK’s National Institute for Health and Care Excellence (NICE) the COVID-19 ...
Blog
How RWE can support safety in Europe: Dr. Pierre Engel on leveraging innovative strategies to meet regulatory requirements
In Europe as in the U.S., biopharma organizations, regulators, and health technology ...
Blog
Research spotlight: Using RWE to assess molecular insights, published in Science
Earlier this year, Aetion co-authored a study published in Science that demonstrates how ...
Blog
Leveraging RWE in regulatory submissions of medical devices: Three takeaways for medical device and diagnostic companies
The U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological ...
Blog
Research spotlight: Using RWD to evaluate risk of COVID-19 reinfection
To date, approximately 66 million patients have recovered from COVID-19, globally. As the ...
Blog
Research spotlight: Understanding and correcting bias in RWE studies
Real-world evidence (RWE) studies are often criticized for their susceptibility to ...
Blog
How RWE can support drug development during COVID-19 and beyond: Q&A with Dr. Diana Brainard of Gilead Sciences
The COVID-19 pandemic introduced novel challenges for global biopharma organizations, as ...
Blog
How RWE can advance understanding of—and boost public confidence in—COVID-19 vaccine safety
After nearly one year of suffering, isolation, and economic downturn on an unprecedented ...
Blog
Opportunities to advance RWE in Europe: Assessing today’s landscape and priorities for future guidance
Real-world evidence (RWE) has emerged as an important tool for global regulators, health ...
Blog
How medical device companies can use RWE to drive impact for patients: Q&A with Christian Howell, Aetion’s VP/GM of Medical Devices and Diagnostics
For medical device manufacturers, real-world data (RWD) and real-world evidence (RWE) are ...
Blog
Sourcing global real-world data to support R&D: Q&A with Ian Rentsch, VP of Growth and Strategic Partnerships, Aetion
Biopharma organizations are working to incorporate real-world evidence (RWE) throughout ...